GeneDx Forecasts Q1 $113M Revenue and Deepens 2026 Loss Forecast to $1.38 EPS
WGS•GeneDx Holdings forecasts Q1 2026 revenue of $112.96 million and an EPS loss of $0.56 after posting $120.99 million in Q4 revenue and a $0.61 per share loss. Full-year 2026 revenue estimates rose to $550.22 million while EPS forecasts deepened to a $1.38 loss, with targets implying 128.87% upside.
1. Q1 2026 Forecast
GeneDx projects Q1 2026 revenue of $112.96 million, reflecting anticipated demand in its genetic testing services, and expects an EPS loss of $0.56 per share. This follows Q4 results of $120.99 million in revenue, which beat estimates by 0.48%, alongside a $0.61 per share loss that missed forecasts.
2. Full-Year 2026 and 2027 Estimate Trends
Analyst revenue estimates for full-year 2026 have climbed from $534.33 million to $550.22 million, while EPS estimates have worsened from -$1.34 to -$1.38 per share. For 2027, revenue forecasts rose from $648.37 million to $692.85 million and EPS projections shifted from a $0.10 profit to a -$1.42 loss.
3. Analyst Price Targets and Recommendations
The average one-year price target across nine analysts is $143.89, implying a 128.87% upside from current levels, with a high estimate of $177.00 and a low of $90.00. Based on internal valuation models, the one-year GF Value is $79.89, suggesting 27.07% upside, and the consensus brokerage rating of 1.7 indicates an Outperform stance.
